CO5160328A1 - Derivados de etan sulfonil-piperidina - Google Patents

Derivados de etan sulfonil-piperidina

Info

Publication number
CO5160328A1
CO5160328A1 CO00042340A CO00042340A CO5160328A1 CO 5160328 A1 CO5160328 A1 CO 5160328A1 CO 00042340 A CO00042340 A CO 00042340A CO 00042340 A CO00042340 A CO 00042340A CO 5160328 A1 CO5160328 A1 CO 5160328A1
Authority
CO
Colombia
Prior art keywords
piperidina
sulfonil
etan
derivatives
means hydrogen
Prior art date
Application number
CO00042340A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Bernd Buttelmann
Neidhart Marie-Paule Heitz
George Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5160328A1 publication Critical patent/CO5160328A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuesto de fórmula general:<EMI FILE="00042340_1" ID="1" IMF=JPEG >En donde,R1 significa hidrógeno o hidroxilo;R2 significa hidrógeno o metilo; yX significa -O- ó -CH2-;Y a sus sales de adición ácida farmacéuticamente aceptables.
CO00042340A 1999-06-08 2000-06-07 Derivados de etan sulfonil-piperidina CO5160328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08

Publications (1)

Publication Number Publication Date
CO5160328A1 true CO5160328A1 (es) 2002-05-30

Family

ID=8238316

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00042340A CO5160328A1 (es) 1999-06-08 2000-06-07 Derivados de etan sulfonil-piperidina

Country Status (38)

Country Link
US (1) US6310213B1 (es)
EP (1) EP1189886B1 (es)
JP (1) JP3645856B2 (es)
KR (1) KR100571162B1 (es)
CN (1) CN1142141C (es)
AR (1) AR024282A1 (es)
AT (1) ATE315025T1 (es)
AU (1) AU770787B2 (es)
BR (1) BR0011419A (es)
CA (1) CA2376091C (es)
CO (1) CO5160328A1 (es)
CZ (1) CZ299483B6 (es)
DE (1) DE60025348T2 (es)
DK (1) DK1189886T3 (es)
EG (1) EG26101A (es)
ES (1) ES2254183T3 (es)
GC (1) GC0000256A (es)
GT (1) GT200000089A (es)
HK (1) HK1046412B (es)
HR (1) HRP20010885B1 (es)
HU (1) HU228591B1 (es)
IL (2) IL146750A0 (es)
JO (1) JO2260B1 (es)
MA (1) MA26797A1 (es)
MX (1) MXPA01012585A (es)
MY (1) MY128818A (es)
NO (1) NO320613B1 (es)
PA (1) PA8496601A1 (es)
PE (1) PE20010218A1 (es)
PL (1) PL196053B1 (es)
RS (1) RS50033B (es)
RU (1) RU2242464C2 (es)
SI (1) SI1189886T1 (es)
TN (1) TNSN00125A1 (es)
TR (1) TR200103532T2 (es)
TW (1) TWI254043B (es)
WO (1) WO2000075109A1 (es)
ZA (1) ZA200109706B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136475B1 (en) * 2000-03-22 2004-08-18 F. Hoffmann-La Roche Ag Piperidine and piperazine compounds for use in the treatment of Alzheimer
AU7394201A (en) 2000-04-20 2001-11-07 Hoffmann La Roche Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
WO2002031499A1 (en) * 2000-10-09 2002-04-18 Unisearch Limited Detection of neurodegenerative disorders
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
BRPI0909378A2 (pt) * 2008-03-27 2015-10-06 Evotec Neurosciences Gmbh métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b
WO2013012871A1 (en) * 2011-07-18 2013-01-24 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
KR20020008850A (ko) 2002-01-31
HK1046412B (zh) 2004-07-09
HU228591B1 (hu) 2013-04-29
HRP20010885B1 (en) 2010-07-31
EP1189886A1 (en) 2002-03-27
AU770787B2 (en) 2004-03-04
PL352723A1 (en) 2003-09-08
PE20010218A1 (es) 2001-02-28
CA2376091C (en) 2006-03-14
PA8496601A1 (es) 2001-12-14
HK1046412A1 (en) 2003-01-10
CA2376091A1 (en) 2000-12-14
DK1189886T3 (da) 2006-05-15
AR024282A1 (es) 2002-09-25
BR0011419A (pt) 2002-02-26
CN1142141C (zh) 2004-03-17
TR200103532T2 (tr) 2002-05-21
CZ299483B6 (cs) 2008-08-13
ATE315025T1 (de) 2006-02-15
WO2000075109A1 (en) 2000-12-14
MA26797A1 (fr) 2004-12-20
HUP0201916A2 (en) 2002-10-28
GC0000256A (en) 2006-11-01
CZ20014349A3 (cs) 2002-05-15
EP1189886B1 (en) 2006-01-04
JP3645856B2 (ja) 2005-05-11
US6310213B1 (en) 2001-10-30
YU86501A (sh) 2004-09-03
MXPA01012585A (es) 2002-04-10
HUP0201916A3 (en) 2003-05-28
JO2260B1 (en) 2004-10-07
SI1189886T1 (sl) 2006-04-30
RU2242464C2 (ru) 2004-12-20
GT200000089A (es) 2001-11-29
ES2254183T3 (es) 2006-06-16
EG26101A (en) 2013-02-17
PL196053B1 (pl) 2007-11-30
CN1354745A (zh) 2002-06-19
MY128818A (en) 2007-02-28
HRP20010885A2 (en) 2004-02-29
DE60025348D1 (de) 2006-03-30
IL146750A0 (en) 2002-07-25
JP2003501415A (ja) 2003-01-14
ZA200109706B (en) 2003-02-26
TWI254043B (en) 2006-05-01
NO20015920L (no) 2001-12-04
KR100571162B1 (ko) 2006-04-17
AU5218100A (en) 2000-12-28
NO320613B1 (no) 2005-12-27
DE60025348T2 (de) 2006-08-24
RS50033B (sr) 2008-11-28
TNSN00125A1 (fr) 2005-11-10
IL146750A (en) 2006-12-10
NO20015920D0 (no) 2001-12-04

Similar Documents

Publication Publication Date Title
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
PT1299409E (pt) Compostos organicos
TR199700419A2 (xx) Yeni piridazinon t�revleri.
PT1109812E (pt) Pirrolobenzodiazepinas
CO5310534A1 (es) Nuevos derivados de androstano anti-inflamatorios
ATE280763T1 (de) Matrix-metalloproteinase-hemmer
IS6309A (is) Kínasólínafleiður
PT1200426E (pt) Tieno-3-il-sulfonilamino (tio) carbonil-triazolino (ti) onas substituidas
RS50229B (sr) Analozi vitamina d3
CO5160328A1 (es) Derivados de etan sulfonil-piperidina
RS49965B (sr) Supstituisani bisindolmaleimidi za inhibiciju ćelijske proliferacije
CO5261538A1 (es) Nuevos acidos (aminopropil) metilfosfinicos
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
BR9510429A (pt) Composto composição farmacêutica processo para produzir o composto e uso do composto
CO5271679A1 (es) Inhibidores de proteasa 7-14 miembros
ATE348800T1 (de) 4&#39;-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
CO5261576A1 (es) Compuestos
CO5271703A1 (es) Compuestos quimicos
ES2189736T3 (es) Derivados de la benzamida y medicamentos que los contienen.
CO5090902A1 (es) Pirroles sustituidos
CO5130024A1 (es) Derivados de azabicicloheptano n-sustituidos. .
CO5221125A1 (es) Inhibidor de intercambiador de sodio hidrogeno de tipo 1
CO5270005A1 (es) Un nuevo proceso de prepracion de derivados del 2-amino indano